ArticleDiscover oncology2025
Identification and validation of prognostic genes for lung adenocarcinoma prognosis based on PANoptosis-related genes.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of Inflammatory Cell Death-Related Prognostic Signature and Its Regulatory Mechanism in Lung Adenocarcinoma.Cancer medicine · 2026Article
- BUB1B is a novel prognostic-related biomarker and correlated with immune infiltrates in lung adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPANoptosis, a newly identified form of cell death, has been linked to both the destruction of cancer cells and the regulation of antitumor immunity. This study aimed to establish a PANoptosis-related signature associated with lung adenocarcinoma (LUAD), highlighting its role in LUAD pathogenesis.
methodsTranscriptome data from the TCGA-LUAD dataset were analyzed to identify PANoptosis-related differentially expressed genes (PANR-DEGs). A LUAD gene signature was developed using Cox regression and LASSO analyses. The study also evaluated somatic mutations, the immune microenvironment, and immunotherapy potential across two risk groups. Additionally, prognostic gene expression was validated clinically by reverse transcription-quantitative PCR (RT-qPCR).
resultsThe TCGA-LUAD dataset revealed 520 PANR-DEGs. A prognostic signature based on six key genes-CDCP1, CLIC6, FURIN, KRT6A, MFI2, and P2RY13-was constructed. Prognostic analysis indicated that pathological T and N statuses, along with the risk score, could serve as independent prognostic markers. Significant differences in the immune microenvironment were observed between the two risk groups, with TP53 showing the highest mutation frequency. Drug sensitivity assays suggested that the PANoptosis-related gene signature could serve as a predictive tool for therapy. Elevated expression levels of CDCP1, CLIC6, FURIN, KRT6A, and MFI2 were observed in tumor tissues compared to normal tissues. RT-qPCR results confirmed the findings from the bioinformatic analysis.
conclusionA prognostic signature composed of CDCP1, CLIC6, FURIN, KRT6A, MFI2, and P2RY13, based on PANR-DEGs, provides a theoretical framework and reference for further LUAD research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.